PTEN deletion is rare but often homogeneous in gastric cancer

Journal of Clinical Pathology

Volumn 65, Issue 8, 2012, Pages 693-698

  Mina, Sormeh ^a   Bohn, Benjamin A ^a   Simon, Ronald ^a   Krohn, Antje ^a   Reeh, Matthias ^a   Arnold, Dirk ^a   Bokemeyer, Carsten ^a   Sauter, Guido ^a   Izbicki, Jakob R ^a   Marx, Andreas ^a   Stahl, Phillip R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; DISTANT METASTASIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC HETEROGENEITY; GENOME; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY; TISSUE SECTION; VALIDATION PROCESS;

ADENOCARCINOMA; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HEMIZYGOTE; HOMOZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; RISK ASSESSMENT; RISK FACTORS; STOMACH NEOPLASMS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864540451     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200525     Document Type: Article

References (42)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50. (Pubitemid 46655601)
2. Hartgrink HH, Jansen EP, van Grieken NC, et al. Gastric cancer. Lancet 2009;374:477-90.
3. De Vita F, Giuliani F, Silvestris N, et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 2010;36(Suppl 3):S11-15.
4. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
5. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7. (Pubitemid 27148818)
6. Maehama T, Dixon JE. The tumour suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-8. (Pubitemid 28268370)
7. Blanco-Aparicio C, Renner O, Leal JF, et al. PTEN, more than the AKT pathway. Carcinogenesis 2007;28:1379-86. (Pubitemid 47243536)
8. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010;16:34-44.
9. Esteva FJ, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010;177:1647-56.
10. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th edn. New York; London: Springer, 2002.
11. Simon R, Mirlacher M, Sauter G. Tissue microarrays. Methods Mol Med 2005;114:257-68.
12. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. (Pubitemid 351724903)
13. Oki E, Kakeji Y, Baba H, et al. Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer. J Gastroenterol Hepatol 2006;21:814-18. (Pubitemid 43793276)
14. Oki E, Baba H, Tokunaga E, et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005;117:376-80. (Pubitemid 41429560)
15. Li YL, Tian Z, Wu DY, et al. Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. World J Gastroenterol 2005;11:285-8. (Pubitemid 40125221)
16. Byun DS, Cho K, Ryu BK, et al. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer 2003;104:318-27. (Pubitemid 36249814)
17. Chang JG, Chen YJ, Perng LI, et al. Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract. Eur J Cancer 1999;35:647-51.
18. Furuya T, Uchiyama T, Murakami T, et al. Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. Clin Cancer Res 2000;6:2815-20. (Pubitemid 30482122)
19. Osterheld MC, Caron L, Demierre M, et al. DNA-ploidy in advanced gastric carcinoma is less heterogeneous than in early gastric cancer. Cell Oncol 2004;26:21-9. (Pubitemid 39108240)
20. Wen YG, Wang Q, Zhou CZ, et al. Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncol Rep 2010;24:89-95.
21. Guo CY, Xu XF, Wu JY, et al. PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer. World J Gastroenterol 2008;14:3804-11.
22. Lima EM, Araújo JJ, Harada ML, et al. Molecular study of the tumour suppressor gene PTEN in gastric adenocarcinoma in Brazil. Clin Exp Med 2005;5:129-32. (Pubitemid 41597273)
23. Wang JY, Huang TJ, Chen FM, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas. Virchows Arch 2003;442:437-43.
24. Sato K, Tamura G, Tsuchiya T, et al. Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer. Virchows Arch 2002;440:160-5. (Pubitemid 34169853)
25. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002;82:285-91.
26. Cho YJ, Kim JH, Yoon J, et al. Constitutive activation of glycogen synthase kinase-3beta correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancer. BMC Gastroenterol 2010;10:91.
27. Darwish NS, Kim MA, Chang MS, et al. Prognostic significance of CD24 expression in gastric carcinoma. Cancer Res Treat 2004;36:298-302.
28. Lee HS, Lee HK, Kim HS, et al. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003;200:39-46. (Pubitemid 36592634)
29. Bai Z, Ye Y, Chen D, et al. Homeoprotein Cdx2 and nuclear PTEN expression profiles are related to gastric cancer prognosis. APMIS 2007;115:1383-90.
30. Deng H, Wu RL, Zhou HY, et al. Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer. World J Gastroenterol 2006;12:1013-17.
31. Zheng H, Takahashi H, Murai Y, et al. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol 2007;60:273-7. (Pubitemid 46447742)
32. Im SA, Lee KE, Nam E, et al. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori 2005;91:513-21. (Pubitemid 43251123)
33. Zhou YJ, Xiong YX, Wu XT, et al. Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J Gastroenterol 2004;10:3225-9.
34. Wang X, Trotman LC, Koppie T, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007;128:129-39. (Pubitemid 46048884)
35. Wang Q, Zhou Y, Wang X, et al. Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-kappaB inhibition. Cancer Res 2007;67:7773-81. (Pubitemid 47281371)
36. Yang Y, Zhou F, Fang Z, et al. Post-transcriptional and post-translational regulation of PTEN by transforming growth factor-beta1. J Cell Biochem 2009;106:1102-12.
37. Sircar K, Yoshimoto M, Monzon FA, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009;218:505-13.
38. Korshunov A, Sycheva R, Gorelyshev S, et al. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol 2005;18:1258-63. (Pubitemid 43079926)
39. Dellas A, Jundt G, Sartorius G, et al. Combined PTEN and p27kip1 protein expression patterns are associated with obesity and prognosis in endometrial carcinomas. Clin Cancer Res 2009;15:2456-62.
40. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27. (Pubitemid 39485684)
41. Xue L, Zhang X, Li Y, et al. Differences of immunophenotypic markers and signaling molecules between adenocarcinomas of gastric cardia and distal stomach. Hum Pathol 2011;42:594-601.
42. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011;470:214-20.